Arbutus Biopharma Corporation (ABUS)
| Market Cap | 317.48M |
| Revenue (ttm) | 6.15M |
| Net Income (ttm) | -83.24M |
| Shares Out | 79.49M |
| EPS (ttm) | -1.21 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | February 26 |
| Last Price | $3.75 |
| Previous Close | $3.81 |
| Change ($) | -0.06 |
| Change (%) | -1.57% |
| Day's Open | 3.94 |
| Day's Range | 3.66 - 3.95 |
| Day's Volume | 2,415,311 |
| 52-Week Range | 0.88 - 9.02 |
Assembly Biosciences Inc (NASDAQ: ASMB) and Arbutus Biopharma Corp (NASDAQ: ABUS) initiated a Phase 2 trial evaluating the former's vebicorvir (VBR), combined with the latter's AB-729 and stan...
Trial will evaluate Assembly's core inhibitor candidate, vebicorvir, with Arbutus' RNAi therapeutic candidate, AB-729, and standard-of-care NrtI therapy
Arbutus Biopharma Corporation is an industry-leading early clinical-stage biopharmaceutical company focused on developing a cure for patients with chronic hepatitis B virus.
2021 objectives leverage positive momentum in Arbutus' Hepatitis B research and development programs
WARMINSTER, Pa., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people wi...
Investors need to pay close attention to Arbutus Biopharma (ABUS) stock based on the movements in the options market lately.
Investors need to pay close attention to Arbutus Biopharma (ABUS) stock based on the movements in the options market lately.
Repeat dosing of 60 mg AB-729 every 8 weeks resulted in mean HBsAg declines of –1.37 log10 (N=6) comparable to AB-729 dosed every 4 weeks ( –1.44 log10, N=7, p
Data released today expands on November 15, 2020 AASLD presentation
Across all single-dose cohorts, mean HBsAg concentrations continuously declined up to week 12 before reaching a plateau , suggesting dosing of AB-729 less frequently than every 4 weeks may be ...
Investors need to pay close attention to Arbutus Biopharma (ABUS) stock based on the movements in the options market lately.
WARMINSTER, Penn., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people ...
Arbutus Biopharma Corporation (ABUS) CEO Bill Collier on Q3 2020 Results - Earnings Call Transcript
Arbutus (ABUS) delivered earnings and revenue surprises of -35.00% and -15.62%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Arbutus (ABUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Arbutus to Participate in Virtual Fireside Chat at Chardan’s 4th Annual Genetic Medicines Conference
WARMINSTER, Pa., Sept. 28, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people...
Mean HBsAg reduction of 1.23 log10 IU/mL at week 12 with a favorable safety and tolerability profile
WARMINSTER, Pa., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people...
America and the rest of the world is getting ready for a vaccine that will help protect public health against the COVID-19 pandemic.
SOUTH SAN FRANCISCO, Calif. and WARMINSTER, Pa., Aug. 27, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB) and Arbutus Biopharma Corporation (Nasdaq: ABUS), today announced...
Investors need to pay close attention to Arbutus Biopharma (ABUS) stock based on the movements in the options market lately.
Is (ABUS) Outperforming Other Medical Stocks This Year?
Arbutus Biopharma Corporation (ABUS) CEO Bill Collier on Q2 2020 Results - Earnings Call Transcript
Arbutus (ABUS) delivered earnings and revenue surprises of -8.70% and -17.94%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Arbutus Biopharma (NASDAQ:ABUS) fell 1% in pre-market trading after the company reported Q2 results.
Phase 1a/1b clinical trial for AB-729, a subcutaneously delivered RNAi agent, remains on track with results from additional cohorts expected in the second half of 2020
The biotech sector in the stock market has been on fire lately.
WARMINSTER, Pa., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people ...
Here's what drove shares of these healthcare stocks through the roof last month.
Arbutus (ABUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
WARMINSTER, Pa., July 29, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people ...
Arbutus (ABUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The ruling means Moderna may have to pay royalties on its mRNA-based vaccines -- including its coronavirus candidate.
Arbutus Biopharma Corp. (NASDAQ: ABUS) stock has seen an incredible rise over the past few days after the firm won a patent dispute that could have implications for coronavirus vaccine frontru...
Arbutus Biopharma Corp. (NASDAQ: ABUS) shares jumped on Tuesday after the company reported positive data from its early stage clinical trial in patients with chronic hepatitis B virus (HBV) in...
Mean 60 mg HBsAg reduction of 0.99 log10 IU/mL at week 12, with normal ALT and AST values throughout the follow-up period
Arbutus (ABUS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
As of late, it has definitely been a great time to be an investor in Arbutus Biopharma.
Arbutus Biopharma Corporation (ABUS) CEO Bill Collier on Q1 2020 Results - Earnings Call Transcript
Arbutus Biopharma Corporation (ABUS) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Arbutus (ABUS) delivered earnings and revenue surprises of 21.88% and -17.62%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Arbutus Biopharma (NASDAQ:ABUS) rose 12.6% in pre-market trading after the company reported Q1 results.
Arbutus (ABUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Investors need to pay close attention to Arbutus Biopharma (ABUS) stock based on the movements in the options market lately.
Positive single dose AB-729 data in chronic hepatitis B subjects supports further clinical development
Arbutus Biopharma Corporation (ABUS) CEO Bill Collier on Q4 2019 Results - Earnings Call Transcript
Arbutus (ABUS) delivered earnings and revenue surprises of 2.70% and 10.34%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Arbutus (ABUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Arbutus expects to announce AB-729 Preliminary Phase 1a/1b Data late Q12020
About ABUS
Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of AB-836, a capsid inhibitor that has the potential to inhibit HBV replication by preventing the assembly of functional viral capsids; and AB-423, which is in pre-clinical studies. The company also develops RNAi drugs, which utilize the RNA interference pathway, allows for a novel approach t... [Read more...]
| Industry Biotechnology | |
| CEO William Collier | Employees 78 |
| Stock Exchange NASDAQ | Ticker Symbol ABUS |
Financial Performance
In 2019, ABUS's revenue was $6.01 million, an increase of 1.11% compared to the previous year's $5.95 million. Losses were -$153.72 million, 169.4% more than in 2018.
Analyst Forecasts
According to 6 analysts, the average rating for ABUS stock is "Buy." The 12-month stock price forecast is 6.71, which is an increase of 78.93% from the latest price.